Do you want to read an article? Please log in or register.
Real-World Effectiveness of Tofacitinib for Moderate to Severe Ulcerative Colitis: A Multi-Centre UK Experience
Inflammatory Bowel Disease
RECOMMENDED
Related content
RECOMMENDED
Inflammatory Bowel Disease
Tofacitinib for rescue therapy in acute severe ulcerative colitis: a real-world experience
★ 2
Recommended by
Prof. Dr Stephan Vavricka, Faculty Member
J Crohns Colitis.
Kotwani P, Terdiman J, Lewin S
doi: 10.1093/ecco-jcc/jjaa018.
Inflammatory Bowel Disease
Real-world Effectiveness of Advanced Therapies Among Patients With Moderate to Severe Ulcerative Colitis in the United States
Inflamm Bowel Dis.
Long MD, Smith TW, Dibonaventura M, Gruben D, Bargo D, Salese L, Quirk D
doi: 10.1093/ibd/izz204.
Inflammatory Bowel Disease
Use, effectiveness and tolerability of budesonide-MMX in ulcerative colitis: A real-life experience
United European Gastroenterol J.
Maconi G, Mezzina N, Landi S, Grillo S, Bezzio C, Bosani M, Pastorelli L, Dell'Era A, Chibbar R, Carmagnola S, Molteni P, Cassinotti A, Massari A, Ardizzone S
doi: 10.1177/2050640619864257.
Inflammatory Bowel Disease
Real-world effectiveness and safety of Vedolizumab for the treatment of Inflammatory Bowel Disease: The Scottish Vedolizumab Cohort
J Crohns Colitis.
Plevris N, Chuah CS, Allen RM, Arnott ID, Brennan PN, Chaudhary S, Churchhouse AMD, Din S, Donoghue E, Gaya DR, Groome M, Jafferbhoy HM, Jenkinson PW, Lam WL, Lyons M, Macdonald JC, MacMaster M, Mowat C, Naismith GD, Potts LF, Saffouri E, Seenan JP, Sengupta A, Shasi P, Sutherland DI, Todd JA, Veryan J, Watson AJM, Watts DA, Jones GR, Lees CW
doi: 10.1093/ecco-jcc/jjz042.
Inflammatory Bowel Disease
Real-world clinical effectiveness and safety of vedolizumab and anti-tumor necrosis factor alpha treatment in ulcerative colitis and Crohn's disease patients: a German retrospective chart review
BMC Gastroenterol.
Helwig U, Mross M, Schubert S, Hartmann H, Brandes A, Stein D, Kempf C, Knop J, Campbell-Hill S, Ehehalt R
doi: 10.1186/s12876-020-01332-w.
Inflammatory Bowel Disease
Efficacy and safety of biologic agents and tofacitinib in moderate-to-severe ulcerative colitis: A systematic overview of meta-analyses
United European Gastroenterol J.
Pantavou K, Yiallourou AI, Piovani D, Evripidou D, Danese S, Peyrin-Biroulet L, Bonovas S, Nikolopoulos GK
doi: 10.1177/2050640619883566.
Inflammatory Bowel Disease
Tofacitinib in Ulcerative Colitis: Real-world Evidence From the ENEIDA Registry
J Crohns Colitis
Chaparro M, Garre A, Mesonero F, Rodríguez C, Barreiro-de Acosta M, Martínez-Cadilla J, Arroyo MT, Manceñido N, Sierra-Ausín M, Vera-Mendoza I, Casanova MJ, Nos P, González-Muñoza C, Martínez T, Boscá-Watts M, Calafat M, Busquets D, Girona E, Llaó J, Martín-Arranz MD, Piqueras M, Ramos L, Surís G, Bermejo F, Carbajo AY, Casas-Deza D, Fernández-Clotet A, García MJ, Ginard D, Gutiérrez-Casbas A, Hernández L, Lucendo AJ, Márquez L, Merino-Ochoa O, Rancel FJ, Taxonera C, López Sanromán A, Rubio S, Domènech E, Gisbert JP
doi: 10.1093/ecco-jcc/jjaa145
Inflammatory Bowel Disease
Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis
N Engl J Med.
Sands BE, Peyrin-Biroulet L, Loftus EV Jr, Danese S, Colombel JF, Törüner M, Jonaitis L, Abhyankar B, Chen J, Rogers R, Lirio RA, Bornstein JD, Schreiber S, VARSITY Study Group.
doi: 10.1056/NEJMoa1905725.
RECOMMENDED
Inflammatory Bowel Disease
Safety of Tofacitinib in a Real-World Cohort of Patients With Ulcerative Colitis
★ 2
Recommended by
Prof. Dr Stephan Vavricka, Faculty Member
Clin Gastroenterol Hepatol.
Deepak P, Alayo QA, Khatiwada A, Lin B, Fenster M, Dimopoulos C, Bader G, Weisshof R, Jacobs M, Gutierrez A, Ciorba MA, Christophi GP, Patel A, Hirten RP, Colombel JF, Rubin DT, Ha C, Beniwal-Patel P, Ungaro RC, Syal G, Pekow J, Cohen BL, Yarur A
doi: 10.1016/j.cgh.2020.06.050.